Table 5.

Multivariate Cox proportional hazard regression model analysis for DCGL.

		Hazard ratio (95% confidence interval)
		Low-IPV/NRM	High-IPV/NRM	Low-IPV/RM	High-IPV/RM
Overall cohort	Model 1	Ref.	1.73 (1.04–2.86)	0.94 (0.39–2.29)	3.06 (1.78–5.25)
	Model 2	Ref.	1.60 (0.95–2.67)	0.83 (0.34–2.06)	2.50 (1.38–4.52)
	Model 3*	Ref.	1.64 (0.98–2.77)	0.82 (0.33–2.03)	2.47 (1.34–4.56)
PRA positive subgroup	Model 1	Ref.	1.98 (0.77–5.12)	0.71 (0.09–5.79)	3.76 (1.40–10.13)
	Model 2	Ref.	1.91 (0.72–5.07)	0.68 (0.08–5.63)	3.54 (1.22–10.24)
	Model 3†	Ref.	1.96 (0.73–5.22)	0.68 (0.08–5.65)	3.80 (1.27–11.37)
PRA negative subgroup	Model 1	Ref.	1.62 (0.89–2.94)	0.97 (0.36–2.61)	2.79 (1.47–5.33)
	Model 2	Ref.	1.48 (0.80–2.71)	0.83 (0.30–2.28)	2.10 (1.02–4.33)
	Model 3‡	Ref.	1.43 (0.77–2.64)	0.83 (0.30–2.26)	2.12 (1.01–4.42)

Model 1 is the unadjusted model. Model 2 is adjusted with TAC-C0-TWA. Model 3 is adjusted with TAC-C0-TWA and other parameters showing significant differences in baseline characteristics among the four groups according to TAC-IPV and RM/NRM status (^*age, sex, BMI, induction regimen, ^†age, sex, induction regimen, ^‡age, sex, BMI, induction regimen).

BMI, body mass index; DCGL, death-censored graft loss; IPV, intra-patient variability; NRM, non-rapid metabolizer; PRA, panel reactive antibody; Ref., Reference; RM, rapid metabolizer.